 - Subjects receiving oral corticosteroids may continue their use during the study, provided that the dose prednisone 20 mgday or equivalent, budesonide 9 mgday has been stable for 3 weeks prior to the Screening Visit. If oral corticosteroids were recently discontinued, discontinuation must have been completed at least 3 weeks prior to the Screening Visit. Corticosteroid doses should remain stable until the subject is eligible to start corticosteroids tapering, beginning at the Week 12 Visit. 